Us Bancorp \De\ Cel Sci Corp Transaction History

Us Bancorp \De\

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 06, 2024	SELL	$1.11 - $1.85 $11,053 - $18,422	-9,958 Reduced 99.99%	1 $0
Q1 2024 May 07, 2024	BUY	$1.63 - $3.08 $9,176 - $17,340	5,630 Added 130.05%	9,959 $19,000
Q4 2023 Feb 09, 2024	BUY	$1.07 - $3.07 $4,632 - $13,290	4,329 New	4,329 $11,000
Q4 2021 Feb 11, 2022	SELL	$7.1 - $12.82 $1,057 - $1,910	-149 Closed	0 $0
Q3 2021 Nov 10, 2021	SELL	$7.64 - $12.49 $10,100 - $16,511	-1,322 Reduced 89.87%	149 $2,000
Q2 2021 Aug 05, 2021	BUY	$8.68 - $27.49 $729 - $2,309	84 Added 6.06%	1,471 $13,000
Q1 2021 Apr 28, 2021	BUY	$12.0 - $27.64 $5,340 - $12,299	445 Added 47.24%	1,387 $21,000
Q4 2020 Feb 04, 2021	BUY	$11.05 - $16.62 $5,989 - $9,008	542 Added 135.5%	942 $11,000
Q3 2020 Nov 10, 2020	BUY	$11.69 - $14.54 $4,676 - $5,816	400 New	400 $5,000
Q3 2019 Nov 08, 2019	SELL	$6.0 - $9.6 $6 - $9	-1 Closed	0 $0
Q2 2019 Aug 13, 2019	SELL	$3.77 - $8.67 $11 - $26	-3 Reduced 75.0%	1 $0
Q3 2018 Nov 01, 2018	BUY	$0.83 - $4.16 $3 - $16	4 New	4 $0

27.1K

150K

Ticker CVM
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,367,500
Market Cap $26.9M
Description
CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical ...

Get notified when there are updates to the investment portfolio of Us Bancorp \De\, based on Form 13F filings with the SEC.

Stay updated on Us Bancorp \De\ with notifications on news.